These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27083246)

  • 21. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
    Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
    J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy followed by surgery for advanced oesophageal cancer.
    Toxopeus EL; Talman S; van der Gaast A; Spaander VM; van Rij CM; Krak NC; Biermann K; Tilanus HW; Mathijssen RH; van Lanschot JJ; Wijnhoven BP
    Eur J Surg Oncol; 2015 Mar; 41(3):323-32. PubMed ID: 25534280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma.
    Speicher PJ; Englum BR; Ganapathi AM; Mulvihill MS; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
    J Thorac Oncol; 2015 Jan; 10(1):181-8. PubMed ID: 25490005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
    Hayashi Y; Xiao L; Suzuki A; Blum MA; Sabloff B; Taketa T; Maru DM; Welsh J; Lin SH; Weston B; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Ajani JA
    Eur J Cancer; 2012 Dec; 48(18):3396-404. PubMed ID: 22853875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Spierings LE; Lagarde SM; van Oijen MG; Gisbertz SS; Wilmink JW; Hulshof MC; Meijer SL; Anderegg MC; van Berge Henegouwen MI; van Laarhoven HW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S766-71. PubMed ID: 26350367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex Disparities After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer.
    Rowse PG; Jaroszewski DE; Thomas M; Harold K; Harmsen WS; Shen KR
    Ann Thorac Surg; 2017 Oct; 104(4):1147-1152. PubMed ID: 28842111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base.
    Cohen AJ; Packiam V; Nottingham C; Steinberg G; Smith ND; Patel S
    Urol Oncol; 2017 Jan; 35(1):34.e1-34.e8. PubMed ID: 27592529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery.
    Thomas DC; Arnold BN; Rosen JE; Salazar MC; Blasberg JD; Detterbeck FC; Boffa DJ; Kim AW
    Lung Cancer; 2017 Jan; 103():75-81. PubMed ID: 28024700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.
    Zhang JQ; Hooker CM; Brock MV; Shin J; Lee S; How R; Franco N; Prevas H; Hulbert A; Yang SC
    Ann Thorac Surg; 2012 Feb; 93(2):429-35; discussion 436-7. PubMed ID: 22269708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
    Javeri H; Arora R; Correa AM; Hofstetter WL; Lee JH; Liao Z; McAleer MF; Maru D; Bhutani MS; Swisher SG; Izzo JG; Ajani JA
    Cancer; 2008 Sep; 113(6):1302-8. PubMed ID: 18623381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma.
    Zahoor H; Luketich JD; Levy RM; Awais O; Winger DG; Gibson MK; Nason KS
    J Thorac Cardiovasc Surg; 2015 Feb; 149(2):538-47. PubMed ID: 25454907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer.
    Stiles BM; Christos P; Port JL; Lee PC; Paul S; Saunders J; Altorki NK
    J Thorac Cardiovasc Surg; 2010 Feb; 139(2):387-94. PubMed ID: 20006355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N1 esophageal carcinoma: the importance of staging and downstaging.
    Rice TW; Blackstone EH; Adelstein DJ; Zuccaro G; Vargo JJ; Goldblum JR; Rybicki LA; Murthy SC; Decamp MM
    J Thorac Cardiovasc Surg; 2001 Mar; 121(3):454-64. PubMed ID: 11241080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.